The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Second-line treatment of HER2+ metastatic breast cancer (MBC): Trastuzumab (T) beyond progression or lapatinib (L)? A retrospective database study.
Rinat Yerushalmi
Honoraria - GlaxoSmithKline; Roche
Ilan Feldhamer
No relevant relationships to disclose
Sari Greenberg-Dotan
No relevant relationships to disclose
Haim Bitterman
No relevant relationships to disclose
Ariel Hammerman
No relevant relationships to disclose